Search

everythinglearnresearchcommunity

for

Search:↓

Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.

CD3+ T-cell presence is a reliable marker to tell apart alopecia areata from pattern hair loss.

A specific group of skin stem cells was found to help maintain hair follicle cells.

Immune cells boost stem cell activity in hairy moles, causing more hair growth.

CD34⁺ cells help heal damaged limbs by promoting blood vessel growth.

Higher levels of IL-1R1 and hsa-miR-19b-3p may help diagnose and predict alopecia areata severity.

LRIG1 is linked to better survival in Merkel cell carcinoma.

LL-37 helps stem cells grow and move, aiding tissue regeneration and hair growth.

People with rheumatoid arthritis have a higher risk of developing alopecia areata.

RORA affects hair follicle stem cells' structure and movement, potentially helping treat hair loss.

The new Hairless R/J mice model improves imaging for tumor monitoring and cancer therapy evaluation.

Farudodstat may effectively treat alopecia areata without harmful side effects.

Certain human skin cells marked by CD44 and ALDH are rich in stem cells capable of long-term skin renewal.

IL-19 and IL-24 help cells respond to DNA damage and could be targeted for cancer and age-related disease treatments.

Collagen VII helps skin heal and stay strong, sirolimus may lower skin cancer risk in kidney transplant patients, high-molecular-mass hyaluronan helps naked mole rats resist cancer, dermal γδ T cells aid in hair growth in rodents, and overexpression of IL-33 in mouse skin causes itchiness, offering a model for studying allergic inflammation treatments.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.

UDCA reduces inflammation and joint damage in rheumatoid arthritis.

DNAJB9 cfRNA could help diagnose and treat female hair loss.

Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.

KRT17 may be a new target for endometrial cancer treatment because it helps cancer cells move and form new blood vessels.